Research programme: TRPM8 channel inhibitors - RaQualia

Drug Profile

Research programme: TRPM8 channel inhibitors - RaQualia

Alternative Names: CMR-1 anatgonists - RaQualia; RQ-00434739

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator RaQualia Pharma
  • Class Small molecules
  • Mechanism of Action TRPM8 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain; Pain
  • No development reported Inflammation

Most Recent Events

  • 26 Sep 2016 Pharmacodynamics data from a preclinical study presented at the 16th World Congress on Pain (WCP-2016)
  • 02 Sep 2016 Preclinical trials in Neuropathic pain in Japan (unspecified route)
  • 20 Jul 2016 Early research in Neuropathic pain in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top